{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:29Z","timestamp":1793726069502,"version":"4.6.1"},"reference-count":49,"publisher":"ARAN Ediciones","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.hipert.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T07:38:49Z","timestamp":1695454729000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Albuminuria and cardiovascular risk"],"prefix":"10.20960","volume":"40","author":[{"given":"D.H.","family":"Rigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Orias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2023.03.003_bib0250","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1311890","article-title":"Cardiovascular risk and events in 17 low-, middle-, and high-income countries","volume":"371","author":"Yusuf","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0255","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2023.03.003_bib0260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ki.2013.490","article-title":"Microalbuminuria: target for renoprotective therapy PRO","volume":"86","author":"Roscioni","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.hipert.2023.03.003_bib0265","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MNH.0b013e32833e4ce1","article-title":"Albuminuria: all you need to predict outcomes in chronic kidney disease?","volume":"19","author":"Gansevoort","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.hipert.2023.03.003_bib0270","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000516911","article-title":"From proteinuria to fibrosis: an update on pathophysiology and treatment options","volume":"46","author":"Sharma","year":"2021","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.hipert.2023.03.003_bib0275","doi-asserted-by":"crossref","first-page":"F1589","DOI":"10.1152\/ajprenal.00142.2008","article-title":"Disease-dependent mechanisms of albuminuria","volume":"295","author":"Comper","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.hipert.2023.03.003_bib0280","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1152\/physrev.00014.2021","article-title":"Albumin uptake and processing by the proximal tubule: physiological, pathological, and therapeutic implications","volume":"102","author":"Molitoris","year":"2022","journal-title":"Physiol Rev"},{"key":"10.1016\/j.hipert.2023.03.003_bib0285","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3949\/ccjm.81a.13040","article-title":"Albuminuria: when urine predicts kidney and cardiovascular disease","volume":"81","author":"Stephen","year":"2014","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0295","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2014.10.013","article-title":"Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management","volume":"65","author":"Akbari","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hipert.2023.03.003_bib0300","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein\u2013creatinine ratio or urine dipstick protein to urine albumin\u2013creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0305","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2023.03.003_bib0310","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1097\/HJH.0b013e3282ef1c5f","article-title":"Associations of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study","volume":"25","author":"B\u00f6hm","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2023.03.003_bib0315","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/HJH.0000000000000991","article-title":"Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis","volume":"34","author":"Viazzi","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2023.03.003_bib0320","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsuishita","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.03.003_bib0325","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2010.39","article-title":"Relation between kidney function, proteinuria, and adverse outcomes","volume":"303","author":"Hemmelgarn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2023.03.003_bib0330","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hipert.2023.03.003_bib0335","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/1753-0407.13152","article-title":"Low-grade albuminuria is associated with high cardiovascular risk in CVD-free and normoalbuminuric Chinese adults: results from the REACTION study","volume":"13","author":"Li","year":"2021","journal-title":"J Diabetes"},{"key":"10.1016\/j.hipert.2023.03.003_bib0340","unstructured":"SCORE2 and SCORE-OP. www.escardio.org."},{"key":"10.1016\/j.hipert.2023.03.003_bib0345","unstructured":"ASCVD Risk Estimator. https:\/\/tools.acc.org\/ASCVD-Risk-Estimator-Plus\/#!\/calculate\/estimate\/."},{"key":"10.1016\/j.hipert.2023.03.003_bib0350","unstructured":"Hearts en las Am\u00e9ricas. https:\/\/www.paho.org\/es\/hearts-americas\/calculadora-riesgo-cardiovascular."},{"key":"10.1016\/j.hipert.2023.03.003_bib0355","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0360","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1111\/j.1523-1755.2004.09223.x","article-title":"Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial","author":"Hunsicker","year":"2004","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.hipert.2023.03.003_bib0365","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0370","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0375","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.03.003_bib0380","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-139-3-200308050-00006","article-title":"Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial","volume":"139","author":"Devereux","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0385","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.03.003_bib0390","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0395","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0400","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.10681014","article-title":"Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view","volume":"10","author":"Fried","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2023.03.003_bib0405","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MNH.0000000000000541","article-title":"Change in albuminuria as a surrogate endpoint","volume":"28","author":"Waijer","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.hipert.2023.03.003_bib0410","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/ki.2014.98","article-title":"Progressive diabetic nephropathy. How useful is microalbuminuria? contra","volume":"86","author":"MacIsaac","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.hipert.2023.03.003_bib0415","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa021835","article-title":"Regression of microalbuminuria in type 1 diabetes","volume":"348","author":"Perkins","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0420","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archinternmed.2011.16","article-title":"Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications cohort","volume":"171","author":"de Boer","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0425","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/ndt\/gfh470","article-title":"Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria","volume":"19","author":"Gaede","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hipert.2023.03.003_bib0430","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1681\/ASN.2006070738","article-title":"What predicts progression and regression of urinary albumin excretion in the nondiabetic population?","volume":"18","author":"Brantsma","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2023.03.003_bib0435","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0440","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0445","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.03.003_bib0450","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0455","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0460","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2215\/CJN.14901219","article-title":"Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial","volume":"15","author":"Levin","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2023.03.003_bib0465","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jamacardio.2021.0660","article-title":"Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial","volume":"6","author":"Zelniker","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hipert.2023.03.003_bib0470","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0475","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2215\/CJN.15260920","article-title":"Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a CREDENCE secondary analysis","volume":"16","author":"Jardine","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2023.03.003_bib0480","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.03.003_bib0485","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00125-022-05694-6","article-title":"Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial","volume":"65","author":"Waijer","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.hipert.2023.03.003_bib0490","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183723000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183723000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:28Z","timestamp":1784596528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183723000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1889183723000211"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2023.03.003","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albuminuria and cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SEH-LELHA.","name":"copyright","label":"Copyright"}]}}